Skip to main content
Book cover

Drug Discovery pp 19–34Cite as

Captopril

  • Chapter

Abstract

Captopril was the first inhibitor of angiotensin-converting enzyme (ACE) to be effective by the oral route. ACE catalyzes the conversion of angiotensin I, a weakly active product of renin activity, to angiotensin II, a potent vasoconstrictor agent and stimulator of aldosterone secretion (Fig. 1). It is generally agreed that captopril represents a significant therapeutic advance as well as a tool for defining the control mechanisms for sodium balance, extracellular volume maintenance, and blood-pressure regulation. Moreover, some clinicians believe that it is the most significant advance yet in the diagnosis and management of hypertension (Laragh, 1984).

Keywords

  • Snake Venom
  • Renin System
  • Peptidal Angiotensin Converting Enzyme Inhibitor
  • Peptide Bradykinin
  • Lung Circulation

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4612-0469-5_2
  • Chapter length: 16 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-1-4612-0469-5
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   169.99
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Antonaccio, M.-J.: Angiotensin converting enzyme (ACE) inhibitors. Annu. Rev. Pharmacol. Toxicol. 22:57–87, 1982.

    CrossRef  PubMed  CAS  Google Scholar 

  • Atkinson, A. B. and Robertson, J. I. S.: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 2:836–839, 1979.

    CrossRef  PubMed  CAS  Google Scholar 

  • Bakhle, Y. S.: Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 220:919–921, 1968.

    CrossRef  PubMed  CAS  Google Scholar 

  • Bakhle, Y. S.: Inhibition of angiotensin I converting enzyme by venom pep-tides. Br. J. Pharmacol. 43:252–254, 1971.

    CrossRef  PubMed  CAS  Google Scholar 

  • Braun-Menendez, E. and Page, I. H.: Suggested revision of nomenclatureangiotensin. Science 127:242, 1958.

    CrossRef  PubMed  CAS  Google Scholar 

  • Braun-Menendez, E., Fasciolo, J. C., Leloir, L. F., and Muñoz, J. M.: The substance causing renal hypertension. J.Physiol. (London) 98:283–298, 1940.

    PubMed  CAS  Google Scholar 

  • Brunner, H. R., Nussberger, J., and Waeber, B.: The present molecules of converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 7: S2–S11, 1985.

    CrossRef  PubMed  Google Scholar 

  • Brunner, H. R., Gavras, H., Waeber, B., Textor, S. C., Turini, G. A., and Wauters, J. P.: Qinical use of an orally acting converting enzyme inhibitor: Captopril. Hypertension 2:558–566, 1980.

    CrossRef  PubMed  CAS  Google Scholar 

  • Brunner, H. R., Gavras, H., Waeber, B., Kershaw, G. R., Turini, G. A., Vukovich, R. A., McKinstry, D. N., and Gavras, I.: Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann. Intern. Med. 90:19–23, 1979.

    PubMed  CAS  Google Scholar 

  • Byers, L. D. and Wolfenden, R.: Binding of the by-product analog benzyl-succinic acid by carboxypeptidase A. Biochemistry 12:2070–2078, 1973.

    CrossRef  PubMed  CAS  Google Scholar 

  • Case, D. B., Atlas, S. A., Laragh, J. H., Sealey, J. E., Sullivan, P. A., and McKinstry, D. N.: Clinical experience with blockade of the renin-angio-tensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, Captopril) in hypertensive patients. Prog. Cardiovasc. Dis. 21: 195–206, 1978.

    CrossRef  PubMed  CAS  Google Scholar 

  • Case, D. B., Wallace, J. M., Keim, H. J., Weber, M. A., Sealey, J. E.,and Laragh, J. H.: Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N. Engl. J. Med. 296: 641–646, 1977.

    CrossRef  PubMed  CAS  Google Scholar 

  • Case, D. B., Wallace, J. M., Keim, H. J., Weber, M. A., Drayer, J. I. M., White, R. P., Sealey, J. E., and Laragh, J. H.: Estimating renin participation in hypertension. Superiority of converting enzyme inhibitor over Saralasin. Am. J. Med. 61:790–796, 1976.

    CrossRef  PubMed  CAS  Google Scholar 

  • Cohn, J. N. and Levine, T. B.: Angiotensin-converting enzyme inhibition in congestive heart failure: The concept. Am.J.Cardiol. 49:1480–1483, 1982.

    CrossRef  PubMed  CAS  Google Scholar 

  • Collier, J. G., Robinson, B. F., and Vane, J. R.: Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (BPP9a or SQ 20,881) which inhibits converting enzyme. Lancet 1:72–74, 1973.

    CrossRef  PubMed  CAS  Google Scholar 

  • Cushman, D. W. and Cheung, H. S.: Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem. Pharmacol. 20:1637–1648, 1971.

    CrossRef  CAS  Google Scholar 

  • Cushman, D. W., Cheung, H. S., Sabo, E. F., and Ondetti, M. A.: Design of potent competitive inhibitors of angiotensin-converting enzyme. Car-boxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16:5484–5491, 1977.

    CrossRef  PubMed  CAS  Google Scholar 

  • Cushman, D. W., Cheung, H. S., Sabo, E. F., and Ondetti, M. A.: Development and design of specific inhibitors of angiotensin-converting enzyme. Am. J. Cardiol. 49:1390–1394, 1982.

    CrossRef  PubMed  CAS  Google Scholar 

  • Cushman, D. W., Wang, F. L., Fung, W. C., Harvey, C. M., and DeForrest, J. M.: Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypertension 2:294–306, 1989.

    CAS  Google Scholar 

  • Cushman, D. W., Pluscec, J., Williams, N. J., Weaver, E., Sabo, E. F., Kocy, O., Cheung, H. S., and Ondetti, M.A.: Inhibition of angiotensin-converting enzyme by analogs of peptides from Bothrops jararaca venom. Experi-entia 29:1032–1035, 1973.

    CAS  Google Scholar 

  • Davies, R. O., Irvin, J. D., Kramsch, D. K., Walker, J. F., and Moncloa, F.: Ena-lapril worldwide experience. Am. J. Med. 77:23–35, 1984.

    CrossRef  PubMed  CAS  Google Scholar 

  • Drayer, J. I. M. and Weber, M. A.: Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 5 (Suppl. III): 108–113, 1983.

    Google Scholar 

  • Edwards, C. R. W. and Padfield, P. L.: Angiotensin-converting enzyme inhibitors: Past, present, and bright future. Lancet 1:30–34, 1985.

    CrossRef  PubMed  CAS  Google Scholar 

  • Engel, S. L., Schaeffer, T. R., Gold, B. I., and Rubin, B.: Inhibition of pressor effects of angiotensin I and augmentation of depressor effects of bra-dykinin by synthetic peptides. Proc. Soc. Exp. Biol. Med. 140: 240–244, 1972.

    PubMed  CAS  Google Scholar 

  • Engel, S. L., Schaeffer, T. R., Waugh, M. H., and Rubin, B.: Effects of the nonapeptide SQ 20,881 on blood pressure of rats with experimental reno-vascular hypertension. Proc. Soc. Exp. Biol. Med. 143:483–487, 1973.

    PubMed  CAS  Google Scholar 

  • Erdös, E. G.: Enzymes that inactivate polypeptides, in Proceedings of 1st Int. Pharmacol. Meeting, Stockholm, pp. 159–178, Macmillan, New York, 1962.

    Google Scholar 

  • Ferguson, R. K. and Vlasses, P. H.: Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril. Am.Heart. 101:650–656, 1981.

    CrossRef  CAS  Google Scholar 

  • Ferguson, R. K., Vlasses, P. H., and Rotmensch, H. H.: Clinical applications of angiotensin-converting enzyme inhibitors. Am. Heart J. 77:690–698, 1984.

    CAS  Google Scholar 

  • Ferguson, R. K., Turini, G. A., Brunner, H. R., Gavras, H., and McKinstry, D. N.: A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1:775–778, 1977.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ferreira, S. H.: A bradykinin-potentiating factor, (BPF) present in the venom of Bothrops jararaca. Br. J. Pharmacol. Chemother. 24:163–169, 1965.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ferreira, S. H. and Rochae Silva, M.: Potentiation of bradykinin by dimer-captopropanol (BAL) and other inhibitors of its destroying enzyme in plasma. Biochem. Pharmacol. 11:1123–1128, 1962.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ferreira, S. H. and Vane, J. R.: The disappearance of bradykinin and eledoi-sin in the circulation and vascular beds of the cat. Br. J. Pharmac. Chemother. 30:417–424, 1967.

    CrossRef  CAS  Google Scholar 

  • Ferreira, S. H., Bartelt, D. C., and Greene, L. J.: Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9:2583–2593, 1970a.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ferreira, S. H., Greene, L. J., Alabaster, V. A., Bakhle, Y. S., and Vane, J. R.: Activity of various fractions of bradykinin potentiating factor against an-giotensin I converting enzyme. Nature 225:379,380,1970b.

    CrossRef  PubMed  CAS  Google Scholar 

  • Gavras, H.: The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. N. Engl. J. Med. 319: 1541–1543, 1988.

    CrossRef  PubMed  CAS  Google Scholar 

  • Gavras, H., Brunner, H. R., Laragh, J. H., Sealey, J. E., Gavras, I., and Vukovich, R. A.: An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N. Engl. J. Med. 291:817–821, 1974.

    CrossRef  PubMed  CAS  Google Scholar 

  • Gavras, H., Brunner, H. R., Turini, G. A., Kershaw, G. R., Tifft, C. P., Cuttelod, S., Gavras, I., Vukovich, R. A., and McKinstry, D. N.: Anti-hypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14,225 in man. N. Engl. J. Med. 298:991–995, 1978.

    CrossRef  PubMed  CAS  Google Scholar 

  • Goldblatt, H.: The Renal Origin of Hypertension, Charles C. Thomas, Springfield, IL, 1948.

    Google Scholar 

  • Goldblatt, H., Lynch, J., Hanzal, R. F., and Summerville, W. W.: Studies on experimental hypertension. J. Exp. Med. 59:347–379, 1934.

    CrossRef  PubMed  CAS  Google Scholar 

  • Groel, J. T., Tadros, S. S., Dreslinski, G. R., and Jenkins, A. C: Long-term antihypertensive therapy with captopril. Hypertension 5:145–151, 1983.

    Google Scholar 

  • Gross, F.: Angiotensin-converting enzyme inhibition: A developing therapeutic concept. Am. J. Cardiol. 49:1384, 1982.

    CrossRef  PubMed  CAS  Google Scholar 

  • Heel, R. C., Brogden, R. N., Speight, T. M., and Avery, G. S.: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20:409–452, 1980.

    CrossRef  PubMed  CAS  Google Scholar 

  • Helmer, O. M.: A factor in plasma that enhances contractions produced by angiotensin in rabbit aortic strips. Fed. Proc. 14:225, 1955.

    Google Scholar 

  • Helmer, O.M.: Differentiation between two forms of angiotensin by means of spirally cut strips of rabbit aorta. Am. J. Physiol. 188:571–577, 1957.

    PubMed  CAS  Google Scholar 

  • Johnson, J. G., Black, W. D., Vukovich, R. A., Hatch, F. E., Friedman, B. I., Blackwell, C. F., Shenouda, A. N., Share, L., Shade, R. E., Acchiardo, S. R., and Muirhead, E. E.: Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme. Clin. Sci. Mol. Med. 48: (Suppl. 2): 53S–56S, 1975.

    Google Scholar 

  • Johnston, C. I., Arnolda, L., and Hiwatari, M.: Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Drugs 27: 271–277, 1984.

    CrossRef  PubMed  CAS  Google Scholar 

  • Kostis J.B.: Angiotension-converting enzyme inhibitors. Emerging differences and new compounds. Am. J. Hypertension 2:57–64, 1989.

    CAS  Google Scholar 

  • Krieger, E. M., Salgado, H. G, Assan, C. J., Greene, L. L. J., and Ferreira, S. H.: Potential screening test for detection of overactivity of renin-angio-tensin system. Lancet 1:269–271, 1971.

    CrossRef  PubMed  CAS  Google Scholar 

  • Laragh, J. H.: Concept of anti-renin system therapy. Historical perspective. Am. J. Med. 77:1–6, 1984.

    PubMed  CAS  Google Scholar 

  • Materson, B. J.: Monotherapy of hypertension with antiotensin-converting enzyme inhibitors. New concepts in hypertension therapy. Am. J. Med. 77:128–134, 1984.

    PubMed  CAS  Google Scholar 

  • Müller, F. B., Sealey, J. E., Case, D. B., Atlas, S. A., Pickering, T. G., Pecker, M. S., Preibisz, J. J., and Laragh, J. H.: The captopril test for identifying renovascular disease in hypertensive patients. Am. J. Med. 80:633–644, 1986.

    CrossRef  PubMed  Google Scholar 

  • Ng, K. K. F. and Vane, J. R.: Conversion of angiotensin I to angiotensin II. Nature 216:762–766, 1967.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ng, K. K. F. and Vane, J. R.: Fate of angiotensin I in the circulation. Nature 218:144–150, 1968.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ondetti, M. A., Rubin, B., and Cushman, D. W.: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihy-pertensive agents. Science 196:441–444, 1977.

    CrossRef  PubMed  CAS  Google Scholar 

  • Ondetti, M. A., Williams, N. J., Sabo, E. F., Pluscec, J., Weaver, E. R., and Kocy, O.: Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 10:4033–038, 1971.

    CrossRef  PubMed  CAS  Google Scholar 

  • Page, I. H.: Production of persistent arterial hypertension by cellophane perinephritis. J. Am. Med. Assoc. 113:2046–2048, 1939.

    CrossRef  CAS  Google Scholar 

  • Page, I. H.: The renin-angiotensin pressor system, in Hypertension: A Symposium, E. T. Bell, ed., University of Minnesota Press, Minneapolis, 1951.

    Google Scholar 

  • Page, I. H. and Bumpus, F. M.: Angiotensin. Physiol. Rev. 41:331–390, 1961.

    PubMed  CAS  Google Scholar 

  • Page, I. H., Dustan, H. P., and Bumpus, F. M.: A commentary on the measurement of renin and angiotensin. Circulation 32:513,514,1965.

    CrossRef  PubMed  CAS  Google Scholar 

  • Patchett, A. A., Harris, E., Tristram, E. W., Wyvratt, M. J., Wu, M. T., Taub, D., Peterson, E. R., Ikeler, T. J., ten Broeke, J., Payne, L. G., Ondeyka, D. L., Thorsett, E. D., Greenlee, W. J., Lohr, N. S., Hoffsommer, R. D., Joshua, H., Ruyle, W. V., Rothrock, J. W., Aster, S. D., Maycock, A. L., Robinson, F. M., Hirschmann, R., Sweet, C. S., Ulm, E. H., Gross, D. M., Vassil, T. C., and Stone, C.A.: A new class of angiotensin-converting enzyme inhibitors. Nature 288:280–283, 1980.

    CrossRef  PubMed  CAS  Google Scholar 

  • Rochae Silva, M., Beraldo, W. T., and Rosenfeld, G.: Bradykinin, hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am. J. Physiol. 156:261–273, 1949.

    Google Scholar 

  • Romankiewicz, J. A., Brogden, R. N., Heel, R. C., Speight, T. M., and Avery, G. S.: Captopril: An update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs 25:6–40, 1983.

    CrossRef  PubMed  CAS  Google Scholar 

  • Skeggs, L. T., Kahn, J. R., and Shumway, N. P.: The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 103:295–299, 1956.

    CrossRef  PubMed  CAS  Google Scholar 

  • Skeggs, L. T., Marsh, W. H., Kahn, J. R., and Shumway, N. P.: The existence of two forms of hypertensin. J. Exp. Med. 99:275–282, 1954.

    CrossRef  PubMed  CAS  Google Scholar 

  • Stewart, J. M., Ferreira, S. H., and Greene, L. J.: Bradykinin potentiating pep-tide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem. Pharmacol. 20:1557–1567, 1971.

    CrossRef  CAS  Google Scholar 

  • Swales, J. D., Bing, R. R, Heagerty, A., Pohl, J. E. F., Russell, G. I., and Thurston, H.: Treatment of refractory hypertension. Lancet 1:894–896, 1982.

    CrossRef  PubMed  CAS  Google Scholar 

  • Vidt, D. G., Bravo, E. L., and Fouad, F. M.: Captopril. N. Engl. J. Med. 306: 214–219, 1982.

    CrossRef  PubMed  CAS  Google Scholar 

  • Vlasses, P. H., Ferguson, R. K., and Chatterjee, K.: Captopril: Clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure. Pharmacotherapy 2:1–17, 1982a.

    PubMed  CAS  Google Scholar 

  • Vlasses, P. H., Rotmensch, H. H., Swanson, B. N., Mojaverian, P., and Ferguson, R.K.: Low-dose captopril: Its use in mild to moderate hypertension unresponsive to diuretic treatment. Arch. Intern. Med. 142:1098–1101, 1982b.

    CrossRef  PubMed  CAS  Google Scholar 

  • Williams, G. H.: Converting-enzyme inhibitors in the treatment of hypertension. N. Engl.J. Med. 319:1517–1525, 1988.

    CrossRef  PubMed  CAS  Google Scholar 

  • Williams, G. H. and Hollenberg, N. K.: Accentuated vascular and endocrine response to SQ 20,881 in hypertension. N.Engl.J. Med. 297:184–188, 1977.

    CrossRef  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Wellcome Research Laboratories Research, Triangle Park, North Carolina, USA

    Robert A. Maxwell

  2. University of Vermont College of Medicine, Burlington, Vermont, USA

    Shohreh B. Eckhardt

Authors
  1. Robert A. Maxwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shohreh B. Eckhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

Copyright information

© 1990 Springer Science+Business Media New York

About this chapter

Cite this chapter

Maxwell, R.A., Eckhardt, S.B. (1990). Captopril. In: Drug Discovery. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-0469-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-0469-5_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4612-6775-1

  • Online ISBN: 978-1-4612-0469-5

  • eBook Packages: Springer Book Archive